Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorVan Cutsem, Eric
dc.contributor.authorDanielewicz, I.
dc.contributor.authorSaunders, M. P.
dc.contributor.authorPfeiffer, P.
dc.contributor.authorArgilés Martinez, Guillem
dc.contributor.authorBorg, Christophe
dc.date.accessioned2022-09-05T11:46:14Z
dc.date.available2022-09-05T11:46:14Z
dc.date.issued2022-06-01
dc.identifier.citationVan Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argilés G, Borg C, et al. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. Br J Cancer. 2022 Jun 1;126:1548–1554.
dc.identifier.issn1532-1827
dc.identifier.urihttp://hdl.handle.net/11351/8027
dc.descriptionColorectal cancer
dc.description.abstractBackground Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in the TASCO1 trial; here, we present the final overall survival (OS) results. Methods TASCO1 was an open-label, non-comparative phase II trial. Patients (n = 153) were randomised 1:1 to TT-B (trifluridine/tipiracil 35 mg/m2 orally twice daily on days 1–5 and 8–12, and bevacizumab intravenously 5 mg/kg on days 1 and 15 of each 28-day cycle) or capecitabine plus bevacizumab (C-B; capecitabine, 1250 mg/m2 orally twice daily on days 1–14 and bevacizumab 7.5 mg/kg intravenously on day 1 of each 21-day cycle). Final OS was analysed when all patients had either died or withdrawn from the study. Adjusted multivariate regression was used to investigate the effects of pre-specified variables on OS. Results At 1 September 2020, median OS was 22.3 months (95% CI: 18.0–23.7) with TT-B and 17.7 months (95% CI: 12.6–19.8) with C-B (adjusted HR 0.78; 95% CI: 0.55–1.10). No variables negatively affected OS with TT-B. Safety results were consistent with prior findings. Conclusions TT-B is a promising therapeutic regimen in mCRC patients ineligible for intensive chemotherapy.
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.ispartofseriesBritish Journal of Cancer;126
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectCòlon - Càncer - Tractament
dc.subjectRecte - Càncer - Tractament
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshSurvival Analysis
dc.titleFirst-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41416-022-01737-2
dc.subject.decsneoplasias colorrectales
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.subject.decsanálisis de supervivencia
dc.relation.publishversionhttps://doi.org/10.1038/s41416-022-01737-2
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Van Cutsem E] University Hospitals Leuven and KU Leuven, Leuven, Belgium. [Danielewicz I] Wojewodzkie Hospitals in Gdyni/Gdansk Medical University, Gdynia, Poland. [Saunders MP] Christie Hospital NHS Foundation Trust, Manchester, UK. [Pfeiffer P] Odense University Hospital, Odense, Denmark. [Argilés G] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Borg C] University Hospital Besançon, Besançon, France
dc.identifier.pmid35440667
dc.identifier.wos000784850700003
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record